PRE-SEED · AUSTRALIA · HEALTH AI Investor data room
Build the operating layer
for migraine.
Information is fragmented. Care is fragmented. The months between appointments are mostly unsupported. Clea is building the AI-first layer that helps people understand, track, navigate and carry their migraine story into better care.
THE PROBLEM
Migraine is enormous.
The care journey is not built like it.
People are forced to become their own researcher, tracker, referral coordinator, treatment historian and appointment-preparation system while living with a disabling neurological condition.
01Search symptoms
02Understand the pattern
03Research treatments
04Track attacks
05Find appropriate care
06Prepare the appointment
07Remember what happened
08Repeat
Australian burden figures are based on the 2018 Deloitte Access Economics whitepaper republished by Migraine Australia. WHO reports migraine among the highest neurological burdens globally. Source
THE CLEA MODEL
Not another migraine website.
A connected migraine system.
Free information wins trust and acquisition. My Clea creates longitudinal engagement. Care navigation turns intent into care. Clinics pay for workflow infrastructure.
AI knowledge
Ask Clea explains migraine information and, for members, organises their own Clea history without diagnosing or prescribing.
Longitudinal context
Daily migraine check-ins, treatment history, saved/followed topics, reports and appointment context create a consented longitudinal record.
National care graph
Specialist profiles plus official public referral pathways create an increasingly complete map of migraine care in Australia.
Clinic workflow
Patient-authorised handoffs, booking flows, AI-assisted summaries and recurring clinic SaaS move Clea into clinical workflow without replacing clinical judgement.
Governance
Source provenance, clinical-review records, AI boundaries, privacy controls, exportability and audit trails are built into the product.
Acquisition flywheel
Search and AI discovery feed accounts; accounts feed tracking and care; clinics feed distribution; longitudinal use strengthens the moat.
WHY NOW
The funding market is rewarding proof, AI and healthcare infrastructure.
Clea is deliberately being built toward where capital and M&A are concentrating rather than where health content looked attractive five years ago.
of healthcare investment in 2025 went to AI-enabled companies, according to SVB.
SVB's H2 2026 view: investors are writing fewer checks and concentrating capital in companies with results, clinical data or commercial momentum.
of healthtech investment dollars in SVB's 2025 report went to provider operations, where AI can demonstrate clearer workflow ROI.
WHAT COMPOUNDS
Every user should make the platform more strategically valuable.
Owned distribution
Evidence-backed content, AI search visibility, The Migraine Brief, community and clinic distribution reduce reliance on paid acquisition.
Longitudinal migraine record
Tracking, treatment history and care journeys become more useful the longer a member stays.
Provider graph
Verified clinicians, pathways, services, access rules and availability become a specialty data asset.
Workflow switching cost
Clinics gain patient context, handoffs, booking workflows and outcome reporting rather than a simple lead marketplace.
AI context layer
Clea can explain and organise the member's own record while remaining deterministic where safety requires it.
Governance moat
Clinical review, source lineage, patient consent, data export, AI boundaries and auditability make enterprise adoption easier to diligence.
BUSINESS MODEL
Free where trust compounds.
Paid where workflow value is obvious.
The near-term focus is deliberately narrow: prove clinic SaaS first, then selectively open larger payer, employer and enterprise channels that strengthen the same core network.
Clea Directory
FreeSource-verified public presence. No paid clinical ranking.
Clea Clinic
AU$499 / monthWorkflow, authorised handoffs, booking, AI summaries and patient-journey reporting. AU$4,990 annual prepay option.
Clea Clinic Growth
AU$899 / monthDeeper funnel analytics, additional team access and eligibility for clearly labelled sponsored inventory. AU$8,990 annual option.
Enterprise
ScopedMulti-site clinics, payers, employers and health platforms requiring implementation, reporting or integration.
Sponsored Featured Partner inventory is reported separately from SaaS ARR and never changes clinical ranking, ratings or matching.
THE PRE-SEED
Fund the proof points a buyer will pay for.
The round is sized to get Clea to strong strategic evidence without over-capitalising the business or forcing an unnecessary financing cycle.
TARGETAU$1.5mAU$2.0m hard cap
Product, AI, security & interoperability
Deepen Ask Clea, member context, reporting, APIs, security controls and validated integration foundations.
Clinical & provider network
Clinical review panel, national directory density, service verification and care-navigation operations.
Distribution & clinic GTM
Patient acquisition, clinic sales, onboarding and repeatable commercial distribution.
Data, research & outcomes
Outcome measurement, research/trial infrastructure and diligence-grade cohort analytics.
Legal, regulatory & operations
Privacy, AI governance, contracting, insurance and corporate readiness.
36-MONTH WORK-BACK
Build for strategic optionality from day one.
The goal is not to manufacture a quick flip. The goal is to make Clea strategically expensive to replicate within three years.
Prove the wedge
- Category-leading migraine resource and AI discovery
- Strong D30/D90 repeat-use cohorts
- National source-verified care coverage
- First 20+ paying clinic customers
- Clinical governance and security foundations
Prove repeatability
- Repeatable clinic sales and onboarding
- 75+ paid clinic target
- Enterprise / payer pilot evidence
- Longitudinal migraine and care-outcome datasets
- Production API / integration proof
Create buyer urgency
- National category leadership
- Meaningful recurring SaaS revenue
- Strong retention and outcome evidence
- Embedded clinic workflows and provider graph
- Diligence-ready platform with international extension potential
Targets are management objectives, not financial forecasts or guarantees.
FOUNDER
SIMON GREALLY
Built around someone who has already helped category leaders scale.
Simon has spent his career at the intersection of company strategy and the market: positioning, launches, international growth, brand and distribution.
Former Global CMO & Advisor. Harrison.ai publicly reports more than US$240m in capital raised.
Company sourceFormer Global VP Brand during Heidi's international expansion in healthcare AI.
Company sourceHelped launch KIIS in Australia in 2014, one of the country's major commercial media launches.
Helped launch Movember in the UK in 2012, building a movement rather than simply marketing a product.
Founder and CEO experience, including building Indy through acquisition, alongside executive leadership across health, media and consumer businesses.
Former professional athlete across rugby league and union, bringing an operator's bias toward preparation, repetition and execution.
STRATEGIC OUTCOME
The buyer should want the assets, not just the app.
Clea is being built to become a valuable specialty layer for organisations already investing in care navigation, insurer health services, healthcare infrastructure, chronic-condition management and provider intelligence.
Dominant migraine audience
Longitudinal patient context
AI engagement layer
National provider graph
Clinic SaaS ARR
Care outcome evidence
Interoperability
Clinical + AI governance
Pharmaceutical ownership is not Clea's primary exit thesis. Editorial independence and patient trust are strategic assets, not things to trade away for short-term monetisation.
If you believe healthcare becomes AI-native, longitudinal and navigated, this is the wedge.
We are speaking with a small number of investors who understand healthcare infrastructure, AI and strategic category building.
This page is for general information only. It is not an offer, invitation or recommendation to acquire securities. Any fundraising will be conducted through appropriate legal documentation and only in accordance with applicable law.